Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 4:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Osteoporosis, Multiple Myeloma
Interventions
Romosozumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Withdrawn Phase 1 Interventional Accepts healthy volunteers

"PTHrP(1-36) IV Dose Escalation Study"

NCT00177411
Conditions
Osteoporosis
Interventions
Parathyroid Hormone-related Protein
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
24 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Postmenopausal Osteoporosis
Interventions
risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
50 Years and older · Female only
Enrollment
923 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Birmingham, Alabama • Oakland, California • San Diego, California + 16 more
Conditions
Osteoporosis (Senile)
Interventions
doxercalciferol capsules, Hectorol®, Matched Placebo (Capsules)
Drug
Lead sponsor
Creighton University
Other
Eligibility
60 Years to 78 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 1994
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Osteoporosis, Post-Menopausal
Interventions
Raloxifene, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
2
States / cities
Indianapolis, Indiana • Omaha, Nebraska
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women

NCT00918749
Conditions
Postmenopausal Osteoporosis
Interventions
150 mg, 75 mg, 100 mg
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
6
States / cities
Daytona Beach, Florida • Fort Myers, Florida • Honolulu, Hawaii + 3 more
Conditions
Breast Cancer, Osteoporosis
Interventions
Bone Mineral Density
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Conditions
Osteoporosis, Age-Related
Interventions
Not listed
Lead sponsor
Amgen
Industry
Eligibility
Female only
Enrollment
935 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
60
States / cities
Birmingham, Alabama • Chandler, Arizona • Peoria, Arizona + 57 more
Conditions
Osteoporosis
Interventions
risedronate (including placebo)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Not applicable Interventional Accepts healthy volunteers

Moringa Oleifera on Bone Density

NCT03026660
Conditions
Osteoporosis, Osteopenia, Postmenopausal Osteoporosis
Interventions
Moringa Oleifera, Cabbage Placebo
Dietary Supplement
Lead sponsor
Appalachian State University
Other
Eligibility
60 Years to 70 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boone, North Carolina
Conditions
Osteoporosis, Postmenopausal Osteoporosis
Interventions
Placebo, BA058 80 mcg, teriparatide
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
50 Years to 85 Years · Female only
Enrollment
2,463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Lakewood, Colorado • Miami, Florida • North Miami, Florida + 2 more
Conditions
Primary Hyperparathyroidism, Osteoporosis, Postmenopausal
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years to 100 Years · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Osteoporosis, Postmenopausal, Back Pain, Spinal Fracture
Interventions
teriparatide, risedronate, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Female only
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
20
States / cities
Birmingham, Alabama • Montgomery, Alabama • Peoria, Arizona + 17 more
Conditions
Osteoporosis
Interventions
SB-751689
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Up to 65 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Miami, Florida
Completed No phase listed Observational Accepts healthy volunteers Results available

Effects of Exemestane on Bone Strength

NCT01144468
Conditions
Osteoporosis, Breast Cancer
Interventions
Not listed
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years and older · Female only
Enrollment
351 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2022
U.S. locations
2
States / cities
Sacramento, California • Rochester, Minnesota
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants

NCT02109042
Conditions
Osteoporosis, Postmenopausal
Interventions
Blosozumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Conditions
Postmenopausal Osteoporosis
Interventions
Ibandronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Female only
Enrollment
1,711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
142
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 128 more
Conditions
Osteoporosis
Interventions
SB-751689
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
35 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Postmenopausal Osteoporosis, Osteoporosis
Interventions
synthetic hPTH 1-34
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
46 Years to 85 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers

DHEA Augmentation of Musculoskeletal Adaptations to Exercise in Older Women

NCT03227458
Conditions
Low Bone Mass, Osteoporosis, Postmenopausal
Interventions
DHEA, Placebo, Exercise
Other · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years to 85 Years · Female only
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Active, not recruiting Not applicable Interventional

Dried Plums and Bone Health in Postmenopausal Women

NCT02822378
Conditions
Postmenopausal Osteoporosis
Interventions
Dried Plum, Calcium supplement, Vitamin D supplement
Dietary Supplement
Lead sponsor
Penn State University
Other
Eligibility
55 Years to 75 Years · Female only
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
University Park, Pennsylvania
Conditions
Endometrial Hyperplasia, Osteoporosis
Interventions
Bazedoxifene/Conjugated Estrogen, CE 0.45 mg/MPA 1.5mg, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,083 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Upland, California • Inverness, Florida • West Palm Beach, Florida + 6 more
Conditions
Osteoporosis, Osteopenia or Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis Risk, Osteoporotic Fractures, Fragility Fracture, Bone Fracture
Interventions
Cortical Bone Mechanics Technology
Diagnostic Test
Lead sponsor
Ohio University
Other
Eligibility
50 Years to 80 Years · Female only
Enrollment
394 participants
Timeline
2022 – 2023
U.S. locations
5
States / cities
Gainesville, Florida • Jacksonville, Florida • Tampa, Florida + 2 more
Completed No phase listed Observational Results available

Study Evaluating Changes In Mammographic Breast Density

NCT00774267
Conditions
Osteoporosis
Interventions
BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene 60 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more